COMP360 — Topline data
Late 2026
Phase 3 trial complete FDA decision expected year-end 2026Source filing
STIM biotech catalysts & pipeline
NEURONETICS INC · Data as of 2026-09-08
Upcoming catalysts
COMP360 — NDA/BLA submission
by year-end
Compass has completed two Phase 3 studies demonstrating clinically meaningful and durable improvement through at least 26 weeks after just one or two doses, and plans to submit an NDA with the potential for an FDA decision by year-end.Source filing